Corvus Pharmaceuticals, Inc. CRVS

Company Overview

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies that target the immune system. The company operates primarily in the biotechnology and pharmaceutical industries, with research centered on immune-cell signaling pathways and immune modulation technologies intended to treat cancer, autoimmune disorders, and infectious diseases. Corvus has historically concentrated on small-molecule and antibody-based therapeutics, with its pipeline increasingly emphasizing immune-cell activation platforms and cytokine signaling biology.

The company’s principal value drivers are its clinical and preclinical drug candidates, intellectual property portfolio, and strategic development programs. Corvus is particularly known for its work involving ITK inhibition and immune activation pathways, including programs targeting natural killer (NK) cells and T-cell biology. Founded in 2014 and headquartered in Burlingame, California, the company evolved from an oncology-focused developer into a broader immunology-focused enterprise as its pipeline advanced and clinical priorities shifted. Public disclosures, including SEC filings, indicate that Corvus remains largely pre-commercial, with revenue historically derived from collaboration arrangements, licensing activities, and financing transactions rather than product sales.